Hubei Jumpcan Pharmaceutical (600566)
- 24.51
- -0.49-1.96%
Hubei Jumpcan Pharmaceutical (600566) News
Express News | The National Medical Products Administration has approved two innovative drugs for marketing.
Recently, the National Medical Products Administration (NMPA) conditionally approved, via a priority review and approval pathway, Tienogitinib Tablets (brand name: Jientai), a Class 1 innovative drug submitted by Pharmajoy Health (Nanjing) Technology Co., Ltd., for marketing. This drug is indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received systemic therapy and FGFR inhibitor treatment and whose tumors harbor fibroblast growth factor receptor (FGFR) 2 gene fusions or rearrangements. The approval provides a new treatment option for these patients. Recently, the NMPA also approved Xiao’er Tongbian Granules, a Class 1.1 traditional Chinese medicine (TCM) innovative drug submitted by Jiangsu Jichuan Pharmaceutical Group Co., Ltd., for marketing. This product is the first TCM innovative drug approved after the issuance of the Special Provisions on the Registration Management of Traditional Chinese Medicines that is indicated for a TCM syndrome pattern. It functions to strengthen the spleen, promote qi circulation, relieve stagnation, and alleviate constipation, and is indicated for pediatric constipation diagnosed as food accumulation syndrome in TCM, presenting symptoms such as dry and hard stools, difficulty defecating, red tongue, thick and greasy tongue coating, and slippery pulse. The approval offers a new therapeutic option for pediatric constipation. (Securities Times)
HarmonyOS-related stocks report H1 results: down 12.16% year-on-year to RMB 34 billion | Post-market announcements roundup
Wuxi Apptec: U.S. court rules on company's motion for preliminary injunction, challenging the adverse effects during the Section 1260H designation period
Express News | Jichuan Pharmaceutical: Subsidiary Receives Drug Registration Certificates for Xiao'er Tongbian Granules and Mesalazine Sustained-Release Granules
Jichuan Pharmaceutical (SHA: 600566) announced that its wholly owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd., recently received Drug Registration Certificates issued by the National Medical Products Administration (NMPA) for Xiao'er Tongbian Granules (Traditional Chinese Medicine Category 1.1) and Mesalazine Sustained-Release Granules (Chemical Drug Category 3). Xiao'er Tongbian Granules is a proprietary innovative traditional Chinese medicine indicated for pediatric constipation with food stagnation syndrome. Mesalazine Sustained-Release Granules are indicated for the treatment of ulcerative colitis and Crohn’s disease and represent the first such product in China to pass the consistency evaluation. The approval of these drugs will enrich the company’s product portfolio and is expected to positively contribute to its growth, although sales performance remains subject to uncertainties arising from industry policies and other factors.
Jichuan Pharmaceutical (600566.SH): Huang Qurong, a director representing employees, plans to reduce holdings by no more than 96,000 shares of the company.
Gelonghui, August 6 — Jiangsu Jichuan Pharmaceutical Co., Ltd. (SHA: 600566) announced that, due to personal funding requirements, Mr. Huang Qurong, employee representative director of the company, intends to reduce his holdings of the company’s shares by no more than 96,000 shares—equivalent to no more than 0.01% of the company’s total share capital and no more than 25% of his own holdings—via centralized bidding transactions within three months starting from the 15th trading day following the disclosure of this announcement. Additionally, Mr. Yan Hongquan, Deputy General Manager and Chief Financial Officer of the company, plans to reduce his holdings by no more than 85,000 shares—also no more than 0.01% of the company’s total share capital and no more than 25% of his own holdings—through centralized bidding transactions during the same period.
Express News | Innovative drug stocks surged amid volatility, with Taiji Group hitting the daily trading limit.
Innovative drug stocks surged amid volatility, with Taiji Group hitting the daily trading limit, followed by gains in Saisheng Pharma, Jincheng Pharmaceutical, MedChemExpress, Wonbang Pharma, Jiangsu Jichuan Pharmaceutical, and Beijing Shuanglu Pharmaceuticals. According to data compiled by PharmaGo, the total value of China’s innovative drug business development (BD) outbound deals in the first half of 2026 reached USD 99.7 billion—approximately double the amount in 2024 and 73% of the total for 2025. Of this, upfront payments from BD out-licensing agreements totaled approximately USD 5 billion, already accounting for about 70% of the full-year 2025 figure.
Jichuan Pharmaceutical (600566.SH): Has cumulatively repurchased 934,700 shares
Gelonghui, July 1 — Jiangsu Jichuan Pharmaceutical Co., Ltd. (SHA: 600566) announced that as of June 30, 2026, the company has cumulatively repurchased 934,700 shares via centralized bidding transactions, representing 0.10% of its total share capital. The highest purchase price was RMB 27.49 per share and the lowest was RMB 25.94 per share, with a total amount paid of RMB 25 million (excluding transaction fees).
A-Share Market Close: CSI STAR 50 Rises 3.85% to Hit Record High, Semiconductor Sector Surges
Total market turnover amounted to RMB 3.29 trillion.
Jichuan Pharmaceutical (600566.SH) 2025 Annual Profit Distribution: Cash Dividend of RMB 1.74 per Share
Gelonghui, June 23 — Jiangsu Jichuan Pharmaceutical Co., Ltd. (SHA: 600566) announced its 2025 annual profit distribution implementation notice, stating that the company will distribute a cash dividend of RMB 1.74 per share (tax inclusive) to all shareholders, based on the total number of shares entitled to profit distribution—i.e., the total issued shares as of the record date for the equity distribution, excluding shares held in the company’s repurchase account, restricted shares pending repurchase and cancellation, and shares under employee stock ownership plans. As of the date of this announcement, the company's total share capital amounts to 921,731,260 shares, less 1,761,627 shares held in the repurchase account and 33 restricted shares pending repurchase and cancellation.
Jichuan Pharmaceutical and Yusen New Drug have entered into a strategic collaboration on a Class 1.1 innovative traditional Chinese medicine for liver fibrosis.
Gelonghui, June 16 — Recently, Jichuan Pharmaceutical officially signed a cooperation agreement with Yusen Pharmaceuticals for Baqi Rougan Granules, a Class 1.1 traditional Chinese medicine innovative drug. Baqi Rougan Granules is derived from the clinical prescription of Professor Gao Yueqiu, a renowned TCM practitioner in Shanghai. After obtaining approval as a hospital-prepared formulation, it has been used clinically under the name 'Rougan Granules' for patients with hepatic fibrosis due to chronic liver disease.
Jichuan Pharmaceutical (600566.SH): New indication for the co-developed product Baloxavir Marboxil Tablets granted drug registration certificate
Jichuan Pharmaceutical (SHA: 600566) announced that its wholly owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd., has recently received a Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for maseloxavir tablets developed in collaboration with Zhengxiang Pharmaceuticals (Nanjing) Group Co., Ltd. ("Zhengxiang Pharmaceuticals"). The drug has been approved for a new indication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 years and older.
Jichuan Pharmaceutical (600566.SH): Has cumulatively repurchased 934,700 shares.
Gelonghui, June 1 — Jiangsu Jichuan Pharmaceutical Co., Ltd. (SHA: 600566) announced that as of May 31, 2026, the company has cumulatively repurchased 934,700 shares through centralized bidding transactions, representing 0.10% of its total share capital. The highest purchase price was RMB 27.49 per share and the lowest was RMB 25.94 per share, with a total amount paid of RMB 25 million (excluding transaction fees).
Jumpcan Pharma Gains Protection Status for Traditional Chinese Medicine
Hubei Jumpcan Pharmaceutical (SHA:600566) said China's drug regulator granted Pudilan Xiaoyan oral liquid the status of nationally protected traditional Chinese medicine.The drug is used to treat
No plans to inject computing power assets! A nine-day limit-up ST stock issues an unusual trading activity announcement | Post-market announcement highlights
Nine consecutive limit-ups *ST Zhunyou: The company, its controlling shareholder, and actual controller have no plans to inject computing power assets.
Jichuan Pharmaceutical (600566): Earnings Under Temporary Pressure; Optimistic About the Implementation of Innovation and BD-Driven Growth
Event: The company released its 2025 annual report and its Q1 2026 report. In 2025, the company reported operating revenue of RMB 6.219 billion (down 22.43% year over year) and net profit attributable to shareholders of RMB 1.778 billion (down 29% year over year).
Jichuan Pharmaceutical (600566): Results in Line with Expectations, Dividend Value Becomes More Prominent
Event Description: On April 23, 2026, the company released its 2025 annual report and its first-quarter report for 2026. In 2025, the company recorded operating revenue of RMB 6.219 billion, a year-on-year decrease of 22.43%; it actually
Jichuan Pharmaceutical (600566.SH): The company's products have been preliminarily selected for the centralized volume-based procurement of the National Traditional Chinese Medicine Procurement Alliance.
Gelonghui reported on May 7 that Ji Chuan Pharmaceutical (600566.SH) announced its wholly-owned subsidiary, Ji Chuan Pharmaceutical Group Co., Ltd., participated in the centralized volume-based procurement work of the National Traditional Chinese Medicine Procurement Alliance. According to the announcement titled 'Display of Tentative Winning Results for Centralized Volume-Based Procurement of the National Traditional Chinese Medicine Procurement Alliance' released by the Hubei Medical Insurance Service Platform on April 30, 2026, Ji Chuan's product Jianwei Xiaoshi Oral Liquid is tentatively selected for this centralized volume-based procurement. The revenue from the above-mentioned tentatively selected product Jianwei Xiaoshi Oral Liquid in the fiscal year 2025 was RMB 453.5225 million, accounting for 7% of the company’s total operating income in 2025.
Jichuan Pharmaceutical (600566.SH): Cumulative repurchase of 934,700 company shares
Gelonghui, May 7th - Jichuan Pharmaceutical (600566.SH) announced that as of April 30, 2026, the company has cumulatively repurchased 934,700 shares through centralized bidding, accounting for 0.10% of the company’s total share capital. The highest purchase price was RMB 27.49 per share, and the lowest was RMB 25.94 per share. The total amount paid was RMB 25,000,953 (excluding transaction fees).
Jichuan Pharmaceutical (600566) 2025 Annual Report Commentary: Short-Term Earnings Under Pressure; Focus on the Development of New Products
Executive Summary: The company's short-term performance is under pressure due to fluctuations in end-demand and the impact of centralized procurement; however, it continues to maintain a high dividend payout ratio and is expanding its product pipeline through both independent innovation and external collaborations, highlighting its long-term value. Key Investment Highlights: Maintaining an "Add" rating. Adjustments
Jichuan Pharmaceutical (600566): Maintaining a High Cash Dividend Payout Ratio While Bolstering Mid- to Long-Term Growth Through Innovative R&D and Strategic Collaborations
Event: The company released its 2025 annual report, with strong Q4 performance. In 2025, the company recorded operating revenue of RMB 6.219 billion, down 22.43% year on year; net profit attributable to owners of the parent company was RMB 1.778 billion, down 2
Jichuan Pharmaceutical (600566): Performance Under Temporary Pressure in 2025; BD Partnerships Bolster Future Growth
Performance is under pressure in the current phase, but we remain optimistic about the growth potential driven by R&D and BD initiatives, and maintain a "Buy" rating. The company is expected to achieve revenue of RMB 6.219 billion in 2025 (down 22.43% year on year; all subsequent year-on-year comparisons are on a same-period basis), with net profit attributable to owners of the parent company of 1